Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cisplatin and Docetaxel as Neoadjuvant Therapy for NSCLC
NCT00232206Phase 2Terminated
- Start
- May 2005
- Primary completion
- Apr 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of cisplatin and docetaxel in non-small cell lung carcinoma (NSCLC). Primary endpoint: Pathologic Complete and Partial Response Rate. Started May 2005; status: terminated.
02
Drugs
cisplatindocetaxel
03
Conditions
non-small cell lung carcinoma (NSCLC)
Beyond the preview
Go deeper on NCT00232206.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00232206.